APA

Attal M., Richardson P. G., Rajkumar S. V., San-Miguel J., Beksac M., Spicka I., Leleu X., Schjesvold F., Moreau P., Dimopoulos M. A., Huang J. S., Minarik J., Cavo M., Prince H. M., Macé S., Corzo K. P., Campana F., Le-Guennec S., Dubin F. & Anderson K. C. (20200106). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. : Lancet (London, England).

Chicago

Attal Michel, Richardson Paul G, Rajkumar S Vincent, San-Miguel Jesus, Beksac Meral, Spicka Ivan, Leleu Xavier, Schjesvold Fredrik, Moreau Philippe, Dimopoulos Meletios A, Huang Jeffrey Shang-Yi, Minarik Jiri, Cavo Michele, Prince H Miles, Macé Sandrine, Corzo Kathryn P, Campana Frank, Le-Guennec Solenn, Dubin Franck and Anderson Kenneth C. 20200106. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. : Lancet (London, England).

Harvard

Attal M., Richardson P. G., Rajkumar S. V., San-Miguel J., Beksac M., Spicka I., Leleu X., Schjesvold F., Moreau P., Dimopoulos M. A., Huang J. S., Minarik J., Cavo M., Prince H. M., Macé S., Corzo K. P., Campana F., Le-Guennec S., Dubin F. and Anderson K. C. (20200106). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. : Lancet (London, England).

MLA

Attal Michel, Richardson Paul G, Rajkumar S Vincent, San-Miguel Jesus, Beksac Meral, Spicka Ivan, Leleu Xavier, Schjesvold Fredrik, Moreau Philippe, Dimopoulos Meletios A, Huang Jeffrey Shang-Yi, Minarik Jiri, Cavo Michele, Prince H Miles, Macé Sandrine, Corzo Kathryn P, Campana Frank, Le-Guennec Solenn, Dubin Franck and Anderson Kenneth C. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. : Lancet (London, England). 20200106.